✦ LIBER ✦

Everolimus in de novo cardiac transplant recipients: 48-month (M) follow-up

✍ Scribed by J.M. Hare; S. Perrone; H. Eisen; K. McCurry; P. Hauptman; S. Simonsen; M. Crespo; J. Arizon; J. Kobashigawa; J. Jarcho

Book ID: 116518364
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 78 KB
Volume: 24
Category: Article
ISSN: 1557-3117
DOI: 10.1016/j.healun.2004.11.083

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Everolimus in de novo cardiac transplant

Everolimus in de novo cardiac transplant recipients: 24-month follow-up

✍ A. Haverich; E.M. Tuzcu; M. Viganò; L. Pulpon; R.B. Love; R. Dorent; H.J. Eisen; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Influence of Everolimus on Cyclosporine

Influence of Everolimus on Cyclosporine Neoral Pharmacokinetics in Chinese de Novo Cardiac Transplant Recipients

✍ C.-H. Wang; N.-K. Chou; F.-L.L. Wu; W.-J. Ko; C.-I. Tsao; N.-H. Chi; R.-B. Hsu; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 82 KB

81 Early vs. Delayed EVERolimus in De No

81 Early vs. Delayed EVERolimus in De Novo HEART Transplant Recipients

✍ L. Potena; M. Rinaldi; C. Maiello; U. Livi; G. Gerosa; G. Faggian; C. Pellegrini 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 102 KB

12-month safety and efficacy of everolim

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

✍ Helio Tedesco-Silva Jr; Stefan Vitko; Julio Pascual; Josette Eris; John C. Magee 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 504 KB

Safety, tolerability, and efficacy of ev

Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results

✍ Gary Levy; Heinz Schmidli; Jeffrey Punch; Elizabeth Tuttle-Newhall; David Mayer; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

Everolimus is a macrolide immunosuppressive agent with known consistent absorption. In this double-blind study, we examined the safety and tolerability of everolimus vs. placebo in de novo liver transplant recipients. One hundred and nineteen liver allograft recipients were randomized to 1 of 4 grou

Safety and efficacy of everolimus (RAD)

Safety and efficacy of everolimus (RAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: six-month analysis

✍ H. Eisen; R. Dorent; D. Mancini; H. Valantine; M. Vigano; R. Starling; J. Lind; 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 67 KB